Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PIQ
|
|||
| Former ID |
DIB010270
|
|||
| Drug Name |
Methylprednisolone
|
|||
| Synonyms |
Depo-medrol; M-predrol; Medrol; Medrol Acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [1] | |
| Spinal cord injury [ICD-11: ND51.2] | Investigative | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pharmacia And Upjohn Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30O5
|
|||
| Canonical SMILES |
CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
|
|||
| InChI |
1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
|
|||
| InChIKey |
VHRSUDSXCMQTMA-PJHHCJLFSA-N
|
|||
| CAS Number |
CAS 83-43-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
82706, 811679, 855789, 7847473, 7979947, 8154374, 10321588, 11406050, 11466307, 11467427, 11486113, 12159225, 14779784, 14853277, 24870169, 24896564, 29225690, 46504885, 47440566, 47589248, 48259526, 48334797, 48416259, 49698417, 50019481, 50104073, 50139236, 50796061, 53790220, 56311264, 56311302, 56311303, 56311483, 56312634, 56313960, 56313963, 56314026, 56314034, 56424125, 57323679, 57650805, 81093211, 85300841, 85788445, 87560014, 92125124, 92309029, 93576705, 103189214, 103914078
|
|||
| ChEBI ID |
CHEBI:6888
|
|||
| ADReCS Drug ID | BADD_D01433 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Reaction | Reduction | |||
| Experimental Method | High-throughput screening | |||
| Description | Methylprednisolone can be metabolized by gut microbiota through reduction. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Modulator | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class II | ||||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Regulation of Androgen receptor activity | ||||
| AP-1 transcription factor network | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| SIDS Susceptibility Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Endoderm Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088). | |||
| REF 3 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.